Physician profile
Amy Armstead
NPI 1770113763
$6,396.11
in general payments reported to CMS, 2019-2025
34 companies · $370 in 2025
The $370 reported for 2025 was more than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $608 · 2022: $1,342 · 2023: $2,305 · 2024: $1,771 · 2025: $370.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,445.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,445.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $1,252.50 | 2021-2024 | Enbrel, Otezla, Tavneos |
| Pfizer INC. | $754.67 | 2021-2024 | |
| Janssen Biotech, INC. | $633.61 | 2022-2024 | Tremfya, Simponi, Simponi Aria |
| Mallinckrodt Hospital Products INC. | $533.52 | 2021-2024 | Acthar |
| Ucb, INC. | $322.66 | 2022-2024 | Cimzia |
| Abbvie INC. | $308.65 | 2022-2025 | |
| Glaxosmithkline, LLC. | $284.06 | 2021-2024 | Benlysta, Bexsero, Pediarix |
| E.R. Squibb & Sons, L.L.C. | $262.20 | 2022-2024 | Orencia |
| Astrazeneca Pharmaceuticals LP | $170.31 | 2021-2024 | Saphnelo |
| Janssen Scientific Affairs, LLC | $160.16 | 2022-2024 | Tremfya |
| Ani Pharmaceuticals, INC. | $150.64 | 2022-2024 | Purified Cortrophin Gel |
| Lilly USA, LLC | $140.93 | 2022-2025 | Mounjaro |
| Horizon Therapeutics Plc | $133.53 | 2023 | Krystexxa |
| Novartis Pharmaceuticals Corporation | $129.10 | 2024-2025 | |
| Teva Pharmaceuticals USA, INC. | $124.74 | 2024 | Austedo Xr |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axsome Therapeutics, INC. | $118.71 | 2024 | Auvelity |
| Genzyme Corporation | $116.31 | 2024 | |
| Alexion Pharmaceuticals, INC. | $109.96 | 2022-2024 | Strensiq |
| Aurinia Pharma U.S., INC. | $99.97 | 2021-2023 | Lupkynis |
| Collegium Pharmaceutical, INC. | $68.86 | 2025 | Jornay Pm |
| Bioventus LLC | $58.07 | 2023-2024 | Durolane, Durolane |
| Fresenius Kabi USA, LLC | $57.65 | 2023-2024 | Idacio |
| Vanda Pharmaceuticals INC. | $53.74 | 2025 | Fanapt |
| Boehringer Ingelheim Pharmaceuticals, INC. | $51.35 | 2023 | Spevigo, Cyltezo |
| Sandoz INC. | $49.23 | 2023-2024 | Hyrimoz |
| Organon LLC | $49.03 | 2024 | |
| Octapharma USA, INC. | $45.61 | 2022-2023 | Octagam Immune Globulin (Human) |
| Otsuka America Pharmaceutical, INC. | $42.26 | 2025 | Abilify Asimtufii, Abilify Maintena |
| Alkermes, INC. | $23.31 | 2025 | Aristada, Lybalvi |
| Mylan Institutional INC. | $19.60 | 2023 | Hulio |
| Sobi, INC | $18.16 | 2023 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $18.08 | 2025 | Caplyta |
| Genentech USA, INC. | $17.66 | 2024 | Actemra |
| Pharming Healthcare, INC. | $17.27 | 2023 | Ruconest |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amy Armstead listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.